Stock Price Movement and Senior Notes Redemption - Research Report on Valeant, Edwards Lifesciences, Alkermes, Mallinckrodt, and Dr. Reddy's

NEW YORK, December 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), Edwards Lifesciences Corp (NYSE: EW), Alkermes Plc (NASDAQ: ALKS), Mallinckrodt PLC (NYSE: MNK), and Dr. Reddy's Laboratories Limited (ADR) (NYSE: RDY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Valeant Pharmaceuticals Intl Inc. Research Report  

On December 2, 2013, Valeant Pharmaceuticals International, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., announced the redemption of its remaining $465.5 million aggregate principal amount of its outstanding 6.50% Senior Notes due 2016 (CUSIP Nos. 91911XAR5, U9098VAH5) (the Notes). According to the Company, on November 15, 2013, Valeant Pharmaceuticals International mailed an irrevocable notice of redemption for $450 million aggregate principal amount of the Notes. Additionally, the Company informed that on December 2, 2013, The Bank of New York Mellon Trust Company has mailed a copy of the irrevocable notice of redemption with respect to the remaining Notes to record holders of the Notes, as trustee under the indenture governing the Notes. The Full Research Report on Valeant Pharmaceuticals Intl Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9fdd_VRX

--

Edwards Lifesciences Corp Research Report

On December 3, 2013, shares of Edwards Lifesciences Corp (Edwards Lifesciences) fell 0.52% to $65.13 at the end of trading session. Edwards Lifesciences' stock declined 0.26% over the past three trading sessions, as compared to the Dow Jones Industrial Average Index which declined by 1.14% during the same period. The Full Research Report on Edwards Lifesciences Corp - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/48b8_EW

--

Alkermes Plc Research Report

On December 3, 2013, Alkermes Plc's (Alkermes) stock rose 0.15% to end trading session at $41.12. Over the previous three trading sessions, Alkermes' shares gained 3.32% compared to the Nasdaq composite Index which declined 0.19% during the same period. The Full Research Report on Alkermes Plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e2f3_ALKS

--

Mallinckrodt PLC Research Report

On December 3, 2013, shares of Mallinckrodt PLC (Mallinckrodt) ended the trading session at $51.54, down by 1.47%. Over the previous three trading sessions, Mallinckrodt's stock declined 0.50% as compared to the Dow Jones Industrial Average Index which dropped 1.14% during the same period. The Full Research Report on Mallinckrodt PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/24f6_MNK

--

Dr. Reddy's Laboratories Limited (ADR) Research Report

On December 3, 2013, Dr. Reddy's Laboratories Limited (ADR)'s (Dr. Reddy's) stock dropped 1.25% to end trading session at $39.54. Dr. Reddy's stock rose 0.30% over the past three trading sessions, while the Dow Jones Industrial Average Index dropped 1.14% in the same period. The Full Research Report on Dr. Reddy's Laboratories Limited (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea85_RDY

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED